Trial Profile
Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-Keratinized Squamous Cell Carcinoma of Nasopharynx.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2009
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- Acronyms Tax-Nazo
- Sponsors Sanofi
- 22 May 2009 Primary endpoint changed from disease free survival to complete clinical response rate as reported by ClinicalTrials.gov.
- 09 Nov 2008 New trial record.